logo-loader
viewStarton Therapeutics

Starton Therapeutics CEO talks through 2019 achievements and anticipated milestones in 2020

Starton Therapeutics CEO Pedro Lichtinger sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Lichtinger talks about how the New York-based company recently changed its name from ChemioCare, how the company is well capitalized to continue through Q1 to next year, its anticipate IPO, and recent 'unprecedented results' out of its in multiple myeloma therapy.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Starton Therapeutics named herein, including the promotion by the Company of Starton Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: ChemioCare begins dosing humans with its Olanzapine-based...

ChemioCare CEO Pedro Lichtinger tells Proactive the New York-based biotechnology company focused on transdermal delivery has begun dosing healthy human volunteers with its lead therapy CMIO-OLANZ, an Olanzapine transdermal patch, to treat Poly (ADP-ribose) polymerase (PARP) inhibitor-induced...

on 10/07/2019

2 min read